Kazakhstan

Population 2015  18 million

Tuberculosis profile

- Mortality (excludes HIV+TB)
- Incidence
- Notified (new and relapse)
- Incidence (HIV+TB only)

Notified cases by age group and sex, 2015

- Females
- Males

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2015
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2015
- TB/HIV care in new and relapse TB patients, 2015
- Patients with known HIV-status who are HIV-positive
- on antiretroviral therapy

Drug-resistant TB care, 2015

- Estimated MDR/RR-TB cases among notified pulmonary TB cases
- Estimated % of TB cases with MDR/RR-TB
- % notified tested for rifampicin resistance
- MDR/RR-TB cases tested for resistance to second-line drugs
- Laboratory-confirmed cases
- Patients started on treatment

Drug-resistant TB care, 2015

- New cases
- Previously treated cases
- Total number

Drug-resistant TB care, 2015

- Estimated MDR/RR-TB cases among notified pulmonary TB cases
- Estimated % of TB cases with MDR/RR-TB
- % notified tested for rifampicin resistance
- MDR/RR-TB cases tested for resistance to second-line drugs
- Laboratory-confirmed cases
- Patients started on treatment

Tuberculosis profile

- Mortality (excludes HIV+TB)
- Incidence
- Notified (new and relapse)
- Incidence (HIV+TB only)

Notified cases by age group and sex, 2015

- Females
- Males

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2015
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2015
- TB/HIV care in new and relapse TB patients, 2015
- Patients with known HIV-status who are HIV-positive
- on antiretroviral therapy

Drug-resistant TB care, 2015

- Estimated MDR/RR-TB cases among notified pulmonary TB cases
- Estimated % of TB cases with MDR/RR-TB
- % notified tested for rifampicin resistance
- MDR/RR-TB cases tested for resistance to second-line drugs
- Laboratory-confirmed cases
- Patients started on treatment

Treatment success rate and cohort size

- New and relapse cases registered in 2014
- Previously treated cases, excluding relapse, registered in 2014
- HIV-positive TB cases, all types, registered in 2014
- MDR/RR-TB cases started on second-line treatment in 2013
- XDR-TB cases started on second-line treatment in 2013

TB preventive treatment, 2015

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed
- TB cases on preventive treatment

TB financing, 2016

- National TB budget (US$ millions)

Funding source:

100% domestic, international, 0% unfunded

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2017-04-30

Data: www.who.int/tb/data